This article expresses the opinions of a pharmaceutical microbiologist on the proposed revisions to the EU Good Manufacturing Practice Annex 1 in terms of current industry practice and future innovation in sterile product manufacturing.
As a microbiological consultant working in the pharmaceutical industry, my reaction to the revisions to EU Guidelines to Good Manufacturing Practice – Medicinal Products for Human and Veterinary Use Annex 1. Manufacture of Sterile Medicinal Products was one of disquiet. Although we expect regulatory science to evolve, there is always a tension between industry best practice and the positions taken by regulators. Much of the Annex’s content is, in my opinion, prescriptive, unsupported by technical literature, will not promote a broader understanding of sterile drug manufacturing and may discourage risk analysis.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Can’t attend live? No worries – register to receive the recording post-event.
My major concerns fall into the following four areas:
Requirements in Annex 1 becoming the de facto rules that govern sterile product manufacturing globally when the revised Annex contains requirements that do not represent industry best practice and conflict with other regulatory guidance
Setting microbial requirements for air, surfaces and personnel by air cleanliness classifications of aseptic process environments when they cannot be engineering standards and when these environments vary greatly in design, operation and potential risk of product contamination
Failure to recognise the poor analytical capabilities of current microbial monitoring methods
Continuing to support the equivalency requirement for new microbiological technologies that are not dependent of microbial growth and the colony-forming unit.
Other US viewpoints on the Annex 1 revision from experts in the area of aseptic processing and engineering were published last year.1 Table 1 describes the regulatory framework for GMPs in the US and EU.
The EU GMPs were first published in 1989, reconstructed in October 2005 and updated in December 2010. I believe that Annex 1 dates back to September 2003 and has been revised to align the cleanroom classification table and provide guidance on media simulations, bioburden monitoring and the capping of vials. The current extensive revision published in December 2017 and subject to considerable comment, will be official when finalised. The guidelines are unlikely to be revised again before the passage of a decade. With a “how to” and not a “what to do” approach, the pharmaceutical industry is bound to these mandatory requirements, which will have a dead hand on any advances in manufacturing and monitoring technologies.
The guide is presented in three parts and supplemented by a series of annexes, of which Annex 1. Manufacture of Sterile Medicinal Products is the topic of this article.
The EU Guideline is divided into:
Part I: covering GMP principles for the manufacture of medicinal products
Part II: covering GMP for active substances used as starting materials
Part III: containing GMP-related documents, which clarify regulatory expectations.
These parts of the EU GMPs are high-level requirements comparable to those found in 21 CFR 211 Current Good Manufacturing Practice for Finished Pharmaceuticals.
Differences in sterile product current good manufacturing practice
The 2004 FDA Guidance for Industry Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice is not enforceable but recommends how a sterile drug manufacturer can comply with the cited sections of the GMP regulations and allows other approaches, as justified. In contrast, Annex 1 regulations must be complied with if the manufacturer wants to market their products in the EU. The revision contains many requirements that are not industry practice and are not scientifically justified. I recommend reviewing the recently published 2017 PDA Aseptic Processing Survey to benchmark industry practice.2
The revision was undertaken by a joint EMA and PIC/S working group that represents a broad base of multi-national pharmaceutical manufacturing experience. The Annex 1 revision may make mutual recognition of GMP compliance inspections between the EMA and the FDA more difficult as there are unresolved differences in how to achieve GMP compliance between the two regulatory agencies. Both agencies will retain and exercise the option to conduct separate investigations for cause and pre-approval inspections, where the inspectional differences will be most clearly manifested with one agency taking regulatory action while the other may see no compliance issues. If manufacturing sites outside the EU cannot comply with these changes, this will increase drug shortages in the EU.
Setting microbial requirements by air cleanliness classifications
Setting air cleanliness standards for the engineering design and operation of an aseptic process environment based on particulate concentrations, air velocities, air changes, space pressurisation, temperature and relative humidity makes sense; whereas setting microbial monitoring standards does not, when often they are area use and people related. Aseptic processing environments vary widely in terms of their risk to microbial product contamination from laminar flow hoods to isolator systems. The ability to exclude people from aseptic processing has a hierarchy of risk – laminar flow hood > biological safety cabinets > restricted access barrier systems > open isolator systems > closed isolator systems with gloves > gloveless isolator systems – that is not fully recognised in Annex 1.
Analytical capabilities of current microbial monitoring methods
It is my experience that colleagues in the pharmaceutical industry who are not microbiologists expect too much of microbial monitoring methods, giving more creditability to the plate counts than is justified. These issues are more fundamental than the incubation conditions of environmental monitoring plates and media fills highlighted by the PDA review of the EU GMP Annex 1. Our methods are unreliable for the following reasons:
Microorganisms are never uniformly distributed in the environment so reliable sampling is always an issue, especially at microbial densities
Most microorganisms will not grow on standard microbiological growth media. The term “the great plate count anomaly” was coined by Staley and Konopka to describe the difference in orders of magnitude between the numbers of cells from natural environments that form colonies on agar media and the numbers countable by microscopic examination3
As microorganisms in manufacturing facilities are frequently associated with shed skin cells, water droplets or dust particles, a colony‑forming unit is most likely not derived from a single microbial cell
Microbial levels are set below the limit of quantification where the accuracy and precision of the microbial counts are poor.
Equivalency requirement of new microbiological technologies
The USP general informational chapter <1223> Validation of Alternative Microbiological Methods contains a discussion of the limitations of the colony-forming unit and why microbial detection and enumeration methods that employ different signals to the colony-forming unit may not be equivalent to traditional methods. The signals may include laser-induced fluorescent particles, ATP bioluminescence, enzymic activity, headspace analysis and genomic weights. This was addressed in <1223> by broadening the validation options used to qualify an alternative microbiological method.
Four options are available to establish the equivalence of a candidate alternative analytical method: acceptable procedures (ie, merely meeting a minimum performance or acceptance requirement without a need to demonstrate equivalence to the compendial method); performance equivalence to the compendial method; results equivalence to the compendial method; and decision equivalence to the compendial method.
For example, light-induced fluorescent viable particle monitoring of air and pharmaceutical-grade water can provide continuous in-process monitoring data that is not equivalent to daily or weekly monitoring using colony-forming units obtained from plate counts but may be used to make superior decisions related to a loss of microbial control or adverse trends during sterile product manufacturing. As results are not equivalent, different alert/action levels and trending rules would need to be established, resulting in an improved level of environmental and operational control.4,5,6 The positions taken in the revision to Annex 1 prevent the industry from taking advantage of this new technology.
Furthermore, real-time analysis of the in-process microbiological air quality is consistent with the principles of ICH Q8 Quality Risk Management (QRM), ICH Q9 Quality by Design (QbD) and Process Analytical Technology (PAT).
Conclusions
The working group needs to re-visit the proposed version and make additional changes.
Biography
Dr Tony Cundell has a PhD in Microbiology from the Lincoln University, New Zealand. He consults in the areas of microbial risk assessment, regulatory affairs and microbiological testing. Prior to November 2013 he worked for Merck Research Laboratories in Summit, New Jersey as the Senior Principal Scientist in early phase drug development. Earlier in his career, Tony worked at a director level in Quality Control and Product Development organisations at the New York Blood Center, Lederle Laboratories, Wyeth Pharmaceuticals and Schering-Plough. He is a member of the 2015‑2020 U.S.P. Microbiology Committee of Experts where he takes a leadership role in the area of modern microbiology methods.
References
1. JP. 2018 Annex 1 Misses the Mark pharmtech.com/annex-1-misses-mark-expanded-version March 14 2018
2. PDA Aseptic Processing Survey December 2017, pp169
3. Staley JT, Konopka A. 1985 Measurement of in situ activities of non-photosynthetic microorganisms in aquatic and terrestrial habitats. Ann. Rev Microbiol. 39:321-46.
4. Miller MJ, Walsh MR, Shrake JL, Dukes RE, Hill DB. 2009 Evaluation of the Biovigilant IMD-A, a Novel Spectroscopy Technology for the Continuous and Real-time Monitoring of Viable and Non-viable Particles. Part 2: Case Studies in Environmental Monitoring during Aseptic Filling, Intervention Assessments, and Glove Integrity Testing in Manufacturing Isolators PDA J. Pharm. Sci. & Technol. 63(3): 259-283.
5. Cundell AM. (Workgroup Member) Novel Concept for Online Water Bioburden Analysis: Key Considerations, Applications, and Business Benefits for Microbiological Risk Reduction. Amer. Pharm. Review. Aug.-Sept. 2013 issue, Specification Edition pp 4-7 2013.
6. Hutchins PM. 2016 Real-Time Viable Particle Monitoring: Principles and Benefits for In-Process Measurements. Am. Pharm. Rev. Nov.-Dec. 2016 issue. www.americanpharmaceuticalreview.com
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.